Clinical Trial Results - Cancer Currents Blog
Reports on findings from cancer clinical trials, with commentary from leading researchers on how the trial results will affect patient care.
-
FDA has approved the combination of the immunotherapy drugs ipilimumab (Yervoy) and nivolumab (Opdivo) for the initial treatment of people with advanced colorectal cancer whose tumors are classified as MSI-H or dMMR.
-
In small trials, personalized treatment vaccines appeared to prevent cancer from returning in patients who had successful surgery to remove their tumors. The treatments, which were created based on intensive analyses of patients’ tumors, appeared to be safe.
-
FDA has approved zenocutuzumab (Bizengri) to treat people with pancreatic or non-small cell lung cancer whose tumors have a rare genetic alteration called an NRG1 fusion. The approval is based on a clinical trial in which the drug shrank tumors in a third of patients.
-
Results from a large NCI-funded clinical trial show that a comprehensive program that integrates intensive counseling and cessation medications may be a particularly effective way to help smokers being screened for lung cancer quit.
-
For men with metastatic castration-resistant prostate cancer, initial treatment with enzalutamide (Xtandi) combined with talazoparib (Talzenna) may help them live longer than getting enzalutamide alone, according to updated results from a large clinical trial.
-
Results from two clinical trials show that combining a procedure called TACE with an immunotherapy drug and angiogenesis inhibitor improves how long people with intermediate-stage liver cancer live without their disease returning or getting worse.
-
Following positive results from a clinical trial, the immunotherapy drug blinatumomab (Blincyto) is expected to become part of the standard initial treatment for many kids with B-cell acute lymphoblastic leukemia, the most common form of childhood cancer.
-
In a small clinical trial, an experimental CAR T-cell therapy that targets the protein GD2 on cancer cells shrank tumors—for 2 years or more in several cases—in children and young adults with diffuse midline glioma, an aggressive brain and spinal cord cancer.
-
The findings from a recent NCI-supported clinical trial are helpful because previous studies for people with locally advanced head and neck cancer have yielded conflicting data for and against several alternatives to cisplatin combined with radiation.
-
Younger cancer patients who filled out surveys about their symptoms experienced fewer cancer-related symptoms than those who did not complete the surveys, results from two clinical trials have shown. The findings show patient-reported outcome (PRO) surveys for children can give an accurate picture of how a child is feeling during the stress of treatment.